Ipca Laboratories
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Ipca Laboratories is positioned for robust growth, as management has recently revised revenue and margin guidance upward for FY27, reflecting strong operational momentum and strategic focus on higher-value segments. The company's expansion into biosimilars and generics, particularly in Europe and the US, is expected to drive revenue growth, supported by a healthy balance sheet that allows for continued investment in R&D and capacity expansion. Despite facing challenges from rising input costs and logistics, management's proactive measures, including operational efficiencies and strategic price adjustments, are anticipated to mitigate these pressures. The favorable currency environment further enhances export revenues, aligning with Vista's forecast of accelerating revenue growth and improving margins. Over the next 12-24 months, key opportunities lie in the successful integration of Unichem and the launch of new products, while watchpoints include managing API price volatility and navigating competitive pressures in the biosimilars market
Why We Like This Stock
- Management's upward revision of revenue and margin guidance indicates strong operational momentum and confidence in future growth
- Expansion into biosimilars and generics, particularly in regulated markets, is expected to drive significant revenue growth
- A healthy balance sheet allows for continued investment in R&D and capacity expansion, supporting long-term growth
Things To Watch Out For
- Rising input costs and logistics challenges may pressure profit margins in the short term
- Increased competition in the biosimilars space could impact profitability and market share
- Execution risks related to the integration of Unichem and new product launches may pose challenges to achieving growth targets
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 7,662 | 8,897 | 9,646 | 10,696 | 12,223 |
| Profit Before Tax (Cr.) | 917 | 1,304 | 1,659 | 2,014 | 2,292 |
| PBT Margin | 12.0% | 14.7% | 17.2% | 18.8% | 18.7% |
| Net Profit (Cr.) | 569 | 872 | 1,208 | 1,481 | 1,625 |
| Earnings Per Share | 23.4 | 32.5 | 45.9 | 56.3 | 64.0 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Emkay Global | ▲ Buy | 1,950 | 18-Aug-2026 |
| Nomura | ▲ Buy | 2,060 | 18-Aug-2026 |
| Prabhudas Liladhar | ▲ Buy | 2,000 | 17-Aug-2026 |
| Motilal Oswal | ▲ Buy | 2,060 | 14-Aug-2026 |
Company Overview
Show Company Profile
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetes, diabetology, emollients/protectives, fever, gastroenterology, haematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, regenerative, respiratory, rheumatology, and urology. The company also exports its products to Europe, Africa, the Americas, rest of Asia, the Commonwealth of Independent States, and Australasia. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.